Drug
Zongertinib
Zongertinib: highest development phase Phase 3, developed by Boehringer Ingelheim. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Zongertinib NCT07195695 | Phase 3 | Non-small Cell Lung Cancer |
| Zongertinib NCT07486817 | Phase 2 | Lung Cancer, Non-squamous, Non-small Cell |
| Zongertinib NCT06581432 | Phase 2 | Solid Tumours |
| Zongertinib NCT06324357 | Phase 1/2 | Metastatic Breast Cancer |
| Zongertinib NCT06692322 | Phase 1 | Liver Diseases |
| zongertinib (C-14) NCT05879991 | Phase 1 | Healthy |
Latest
No recent events.
Follow Zongertinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.